Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0000875320-24-000047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-13 | 2024-02-09 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $422.74 | -1,588 | 20.0K | -7% | -$671.3K | |
| 2024-02-13 | 2024-02-12 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $418.77 | -1,738 | 18.3K | -9% | -$727.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | F | D | 1,588 | $422.74 | 20,018 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-12 | S | D | 1,738 | $418.77 | 18,280 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $418.77 (range $418.76 to $418.82). (F2) Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |